Tikva Allocell Presents Preclinical Findings on Armored Allogeneic CD19 CAR T-Cell Therapy for Systemic Lupus Erythematosus
A humanized mouse model showed SB9-armored cells expanded nearly 20-fold more than unarmored cells and produced more sustained B-cell depletion.

Key Points
- Tikva Allocell presented preclinical findings on CD19.SB9.CAR-EBVST, an armored allogeneic CD19 CAR T-cell therapy, as a potential lymphodepletion-free approach for systemic lupus erythematosus.
- In a humanized mouse model, SB9-armored cells expanded nearly 20-fold more than unarmored cells and produced more sustained B-cell depletion.
- In mice engrafted with immune cells from a patient with SLE, treatment depleted B cells and plasma cells and reduced circulating autoantibodies.
Tikva Allocell, a Singapore-based biotechnology company developing off-the-shelf T-cell therapies for cancer and autoimmune diseases, announced that preclinical research evaluating CD19.SB9.CAR-EBVST, its armored allogeneic CD19 CAR T-cell therapy, was presented today in an oral presentation at ACR Convergence 2026 in Orlando, Florida. The therapy uses donor-derived Epstein-Barr virus-specific T cells engineered with a CD19 chimeric antigen receptor and armored with SERPINB9 to resist immune rejection. The presentation highlights its potential as a lymphodepletion-free approach for systemic lupus erythematosus (SLE).
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
The research evaluated donor-derived Epstein-Barr virus-specific T cells (EBVSTs) engineered to express a CD19 chimeric antigen receptor (CAR) and armored with SERPINB9 (SB9) to enhance resistance to immune rejection. In lymphodepletion-free preclinical models, SB9-armored cells demonstrated enhanced persistence and B-cell depletion compared with unarmored CAR-EBVSTs. In a separate mouse model incorporating immune cells from a patient with SLE, treatment depleted B cells and plasma cells and reduced circulating total immunoglobulin G (IgG) and anti-double-stranded DNA (anti-dsDNA) autoantibodies.
Marvin Chew, Ph.D., senior research scientist at Tikva Allocell, delivered the presentation, titled “Preclinical Evaluation of a Lymphodepletion-free Approach for the Treatment of SLE Using an Armored Allogeneic CD19 Chimeric Antigen Receptor Expressing Epstein-Barr Virus Specific T cell Therapy,” during the “Systemic Lupus Erythematosus – Translational Models and Mechanisms” session.
“These preclinical findings support the potential of SB9 armoring to help donor-derived CAR T cells persist and maintain B-cell depletion in the presence of host allogeneic pressure,” said Dr. Chew. “We also observed depletion of B cells and plasma cells, together with reductions in anti-dsDNA autoantibodies, in a model using immune cells from a patient with SLE. These results provide a foundation for further evaluation of this approach as a potential lymphodepletion-free cell therapy for SLE.”
“These data reinforce the potential of our CD19.SB9.CAR-EBVST program and mark an important step in extending our allogeneic CAR T-cell platform into autoimmune diseases,” said Ivan Horak, MD, Founder and CEO of Tikva Allocell. “The enhanced persistence and sustained B-cell depletion observed in these models support our approach to addressing immune rejection and the need for lymphodepletion, which remain central challenges for allogeneic cell therapies. We believe an off-the-shelf therapy that could eliminate the need for lymphodepleting chemotherapy has the potential to broaden access to cell therapy for patients with SLE. We look forward to building on these findings as we advance our work toward accessible treatment options for patients with significant unmet needs.”
Preclinical Findings
Key findings presented at ACR Convergence include:
- Enhanced expansion and sustained B-cell depletion: In mice humanized with CD34-positive hematopoietic stem cells, SB9-armored CD19 CAR-EBVSTs demonstrated nearly 20-fold greater expansion than unarmored CAR-EBVSTs, accompanied by more sustained B-cell depletion, with B-cell recovery following clearance of the CAR-EBVSTs.
- Activity in an SLE patient-derived model: In mice humanized with peripheral blood mononuclear cells (PBMCs) from a patient with SLE, SB9-armored CD19 CAR-EBVST treatment depleted B-cell and plasma-cell populations and reduced circulating total IgG and anti-dsDNA autoantibodies.
- B-cell depletion in patient-derived cell cultures: SB9-armored CD19 CAR-EBVSTs robustly depleted CD19-positive B cells when co-cultured with SLE patient PBMCs, whereas HLA-matched EBVSTs without a CAR did not.
- Resistance to host immune pressure: Armoring with SB9 and a constitutive IL-7 receptor (C7R) increased cell survival in the presence of host allogeneic immune pressure.
Platform and Lead Program
Tikva’s platform uses allogeneic Epstein-Barr virus-specific T cells as the foundation for engineered cell therapies. The company’s SLE research expands the platform beyond oncology, including programs targeting solid tumors. The platform is built on the ALLO SerpinB9 EBVST technology, an allogeneic, virus-specific T-cell technology licensed exclusively from Baylor College of Medicine and enhanced through Tikva’s proprietary protein-engineering strategies. The company describes the platform as integrating tumor-targeting receptors such as B7-H3 with an optimized form of SerpinB9 to help donor-derived T cells resist granzyme-B–mediated immune rejection, persist longer, and minimize graft-versus-host disease with minimal gene editing.
Tikva’s lead program, TAVST01, is an off-the-shelf, B7-H3-targeted EBV-specific T-cell therapy designed for patients with B7-H3-positive solid tumors, including lung, breast, prostate, pancreatic, and pediatric cancers.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Kyverna Therapeutics Reports One-Year Phase 2 Results for CAR T-Cell Therapy in Stiff Person Syndrome
Fate Therapeutics Presents Updated Preliminary Data on iPSC-Derived CAR-T for Active Lupus Nephritis
FDA Clears AbelZeta’s CAR-T Trial for Progressive MS
Fate Therapeutics Launches CAR T Trial for Lupus Nephritis
CREATE Medicines to Launch First Phase 1/2 In Vivo Trial of CAR-T Candidate CRT-402 for Autoimmune Diseases in Australia
Sonoma Biotherapeutics to Automate its Treg Cell Manufacturing Using Cellares’ Cell Shuttle Platform
IN8bio Reports Median Overall Survival of 20.9 Months in Newly Diagnosed Glioblastoma Patients Receiving Repeat-Dose Gamma-Delta T Cell Therapy
UConn Health Launches CAR-T Cell Therapy Program for Blood Cancers







